Microbiome Times - Interview with Accelsiors' Director of Translational Science
Accelsiors is pleased to share this article published in the Microbiome Times in which the leaders of the PRI Clinical Trials Task Group - among them our Director of Translational Science, Prof. Jelena Héléne Cvejic - share their thoughts about the challenges of clinical trials for development of microbiome-based drug products.
What are the main challenges in designing and carrying out LBP clinical trials? Why this innovative field of medicine development requires a new, unique regulatory framework? Why PRI plans to convene stakeholders in a December task group to discuss the appropriate design of clinical trials in MMP/LBP development? Please, click here to read the full article and get answers!
The PRI Clinical Trials Task Group (December 3rd, 2019, Paris) The Clinical Trials Task Group convened by PRI, which will be held on December 3rd, 2019 in Paris, France, will identify key questions relevant to MMP/LBP clinical trial design on the basis of analyzing existing designs for these products, and propose some general approaches for optimizing the success of trials. This task group is open to all PRI member companies planning or developing MMPs (by themselves or with partners) for the European Union market. The organization welcomes companies interested in getting involved in the December discussion group to contact them: contact@pharmabiotic.org |
As a scientifically driven, global, full-service CRO, Accelsiors is pleased to be a partnering member of this main representative organization and leading professional network aimed at developing regulatory intelligence and representing the European Human Microbiome pharmaceutical supply chain. We are glad to join to this cooperation and work with PRI's members together to unlock the potential of the Microbiotic Medicinal Products and translate it into safe, effective and commercially viable therapeutics.